E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Reduction of subcutaneous fat in the submental area |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine the safety and tolerability of ATX-101 injections at three concentrations, relative to placebo. |
|
E.2.2 | Secondary objectives of the trial |
To evaluate the potential efficacy of ATX-101, relative to placebo, in reducing subcutaneous fat in the submental area. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Submental fat that is considered undesirable by the participant and graded by the Investigator as 2 or 3 using the SMF Rating Scale (Appendix C of the protocol). - Males or nonpregnant, nonlactating females who are aged 25 to 65 years, inclusive, on the date of randomization. Females of childbearing potential must have a negative human chorionic gonadotropin (HCG) test result within 28 days before randomization and must agree to practice adequate contraception, in the judgment of the investigator, during the course of the trial. - History of maintenance of a stable body weight, in the judgement of the Investigator, for at least 6 months before randomization. - The subject is expected to comply with and understand the visit schedule and all of the protocol-specified tests and procedures. - The subject is medically able to undergo the administration of study material as determined by clinical and laboratory evaluations (section 7.2 of the protocol) obtained within 28 days before randomization, for which the investigator identifies no clinically significant abnormality. - Signed informed consent obtained before any study specific procedure is conducted. |
|
E.4 | Principal exclusion criteria |
- History of any intervention to treat submental fat (e.g. liposuction) or trauma associated with the chin or neck areas, which in the judgment of the investigator, may affect safety or efficacy evaluation of the treatment. - Loose skin in the neck or chin area for which reduction in submental fat may, in the judgement of the Investigator, result in a cosmetically unacceptable outcome. - Prominent platysmal bands at rest that interfere with the evaluation of submental fat. - Evidence of any cause of enlargement in the submental area (eg. thyroid enlargement, cervical adenopathy) other than localised submental fat. - Fitzpatrick Skin Type IV, V, or VI (Appendix B of the protocol). - Currently on, or considering starting, a weight reduction regimen. - Any medical condition (e.g. respiratory, cardiovascular, hepatic, neurological disease, uncontrolled hypertension, thyroid dysfunction), that would interefere with the assessment of safety or efficacy in this trial or would compromise the ability of the subject to undergo study procedures or to give informed consent. - Treatment with fish oil or nonsteroidal anti-inflammatory agents (NSAIDs) within seven days before randomisation, or any anticipated need for agents with anticoagulative effects (e.g. warfarin, heparin) during the course of the trial. Aspirin used for prophylaxis will be allowed. - Treatment with oral anticoagulants (e.g. warfarin) within 28 days before randomisation. - Treatment with radio frequency, laser procedures, chemical peel, or dermal fillers in the neck or chin area within 12 months before randomization, or botulinum toxin injections within 6 months before randomization. - History of sensitivity to any components of the study material or to topical or local anaesthetics (e.g. lidocaine, benzocaine, novocaine). - Previous randomization into this trial. - Treatment with an investigational device or agent within 30 days before randomization. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Safety endpoints include: - incidence, severity, and duration of all treatment-emergent adverse events - incidence of study material-related adverse events - severity and duration of study material-related adverse events - changes from baseline in clinical laboratory and urinalysis test results - changes from baseline in vital sign and weight measurements |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |